Better Health for All

The company's core business focuses on public health threats, including vaccines and therapeutics, with its product portfolio delivering substantial health benefits. Its Narcan nasal spray, an opioid overdose reversal drug, is now available over-the-counter, with over 20 million doses distributed in 2023, representing an outstanding effort in addiction mitigation.

In response to the mpox outbreak, the company donated 50,000 doses of smallpox vaccine to African countries, demonstrating a significant contribution to global health crisis response. The company has no revenue from products with significant negative health impacts. However, it faced a Class I recall in late 2022/early 2023 for 3,500 units of skin decontamination lotion kits due to leakage, though no injuries or deaths were reported. For this recall, the company issued an urgent notification, demonstrating excellent risk transparency.

Fair Pay & Worker Respect

The company's CEO-to-median employee pay ratio is 13:1.

Employee reviews show an overall rating of 3.3 out of 5 stars , with 56% of employees recommending working at the company and 51% approving of the CEO . No specific regulatory actions, violations, fines, or compliance issues related to labor laws or human rights are mentioned in the provided articles for the company.

Kind to Animals

The company conducts preclinical trials on animals

and utilizes animal models for regulatory approval under the FDA's "Animal Rule" when human efficacy studies are not feasible or ethical. Its policy states adherence to the 3Rs (Reduce, Refine, and Replace) in animal testing. The company also complies with regulations such as the Animal Welfare Act, PHS Policy, USDA requirements, and the Guide for the Care and Use of Laboratory Animals, and mentions AAALAC.

No War, No Weapons

Emergent BioSolutions states it complies with all recognized trade, import, and export controls, boycotts, and sanctions.

The company screens trade partners for reputability to ensure sanctions or other trade control restrictions do not apply to them.

Planet-Friendly Business

The provided article details an FDA warning letter regarding significant violations of Current Good Manufacturing Practice (CGMP) regulations at a drug manufacturing facility

. These violations relate to inadequate cleaning, maintenance, and sterilization of equipment , poor aseptic techniques , and particulate contamination of sterile drug products . The issues cited are related to product quality and safety, not environmental performance or compliance. Therefore, no information relevant to the 'Planet-Friendly Business' ethical value could be found in the provided article.

Safe & Smart Tech

The company reported no material cybersecurity incidents in the past three years.

Its Quality Compliance Management Risk Committee oversees compliance with various areas, including privacy and data security. The Chief Information Security Officer (CISO), who holds CRISC and CIPP/US certifications, reports to this Committee and the Board twice annually. The company uses the NIST framework for assessing third parties. It also maintains security operations metrics, an incident response plan, conducts tabletop exercises, and leverages external consultants for cyber assessments. An internal phishing campaign and awareness program was performed. ERM training is provided to all VP-level and above employees, with annual ERM training for all participants.

Zero Waste & Sustainable Products

Emergent BioSolutions demonstrated extremely poor material efficiency by discarding up to 400 million doses' worth of vaccine ingredients due to manufacturing failures between March 2020 and February 2022.

The company also faced regulatory issues related to waste management, with FDA 483 reports citing a lack of documentation regarding the disposition of non-conforming materials and inadequate waste decontamination at its Baltimore facility.